The challenge of discriminating between HIV‐1, HIV‐2 and HIV‐1/2 dual infections

Abstract

There was accordance between INNO-LIA calls and nucleic acid results, whereas ImmunoComb overestimated the number of HIV-1/2 dually infected patients. Confirmatory typing is needed for patients diagnosed with HIV-1/2 dual infection by ImmunoComb.

Hepatitis B and C in the adult population of Bissau, Guinea‐Bissau: a cross‐sectional survey

“…ImmunoComb HIV 1/2 BiSpot (Orgenics, Yavne, Israel) was used for HIV confirmation and HIV type discrimination. All HIV‐1/2 reactive samples were retyped by INNO‐LIA HIV I/II Score .…”

In VitroAntiviral Activity of Cabotegravir against HIV-2

“…These distinctions complicate HIV treatment in West Africa and other regions where HIV-1 and HIV-2 cocirculate. Difficulties in differentiating HIV-2 or HIV-1/2 dual infection from HIV-1 infection can lead to the inappropriate use of NNRTI-based regimens in HIV-2infected patients and to premature use of PI-based regimens as first-line ART in patients infected solely with HIV-1 (21)(22)(23). Efforts are needed to simplify ART in areas where HIV-1/HIV-2 discriminatory testing is unreliable and stockouts of HIV-2-active antivirals are commonplace (24).…”

HLA‐DQB1*06:276, a novel HLA allele fund in a patient from Guinea‐Bissau

“…3 In extension of this study, we now report a novel HLA-DQB1*06 variant: HLA-DQB1*06:276. The patient was HIV-2 infected as confirmed by INNO-LIA HIV-I/II Score (Fujirebio, Zwijndrecht, Belgium), 4 and the patient was part of the Bissau HIV Cohort. 5 All patients enrolled in the HLA-study 3 had initial HLA genotyping performed by HistoGenetics (Ossining, New York).…”

“…In extension of this study, we now report a novel HLA‐DQB1*06 variant: HLA‐DQB1*06:276. The patient was HIV‐2 infected as confirmed by INNO‐LIA HIV‐I/II Score (Fujirebio, Zwijndrecht, Belgium), and the patient was part of the Bissau HIV Cohort …”